retinamide and Uterine-Cervical-Dysplasia

The patients with cervical precancerous lesions were double-blindly randomized into two groups. The one was treated with retinamide II (RII) suppository intravaginally and the other with placebo, once daily for 50 days as a course. The results showed precancerous lesions in 68.57% of the patients disappeared, with an overall effective rate of 74.29% after two-course treatment with RII. Its long-term curative effect approximated to that with laser beam radiation and electrocautery (P > 0.05), and differed significantly (P < 0.01) from that with common antiphlogistic. So, RII can be used as a major measure in prevention and treatment for cervical cancer in high-incidence areas in our country.

Topics: Administration, Intravaginal; Double-Blind Method; Female; Follow-Up Studies; Humans; Suppositories; Tretinoin; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms